What is ARRY-380, HER2 inhibitor; oral used for?

ARRY-380, HER2 inhibitor; oral is indicated for Breast cancer.

Who makes ARRY-380, HER2 inhibitor; oral?

ARRY-380, HER2 inhibitor; oral is developed by Seagen Inc..

What development phase is ARRY-380, HER2 inhibitor; oral in?

ARRY-380, HER2 inhibitor; oral is in Phase 1.

Last reviewed 2026-04-23 · How we verify

ARRY-380, HER2 inhibitor; oral

Seagen Inc. · Phase 1 active Small molecule

HER2 inhibitor

HER2 inhibitor Used for Breast cancer.

At a glance

Generic name	ARRY-380, HER2 inhibitor; oral
Sponsor	Seagen Inc.
Drug class	HER2 inhibitor
Target	HER2
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 1

Mechanism of action

ARRY-380 is a monoclonal antibody that binds to the HER2 receptor, inhibiting its activity.

Approved indications

Breast cancer

Common side effects

No common side effects on file.

Key clinical trials

A Study of ARRY-380 in Patients With Advanced HER2+ Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARRY-380, HER2 inhibitor; oral CI brief — competitive landscape report
ARRY-380, HER2 inhibitor; oral updates RSS · CI watch RSS
Seagen Inc. portfolio CI